Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells

被引:84
|
作者
Hummel, Richard [1 ,2 ]
Watson, David I. [1 ]
Smith, Cameron [1 ]
Kist, Jakob [1 ]
Michael, Michael Z.
Haier, Joerg [3 ]
Hussey, Damian J. [1 ]
机构
[1] Flinders Univ S Australia, Dept Surg, Flinders Med Ctr, Bedford Pk, SA 5042, Australia
[2] Univ Munster, Dept Gen & Visceral Surg, Munster, Germany
[3] Univ Munster, Ctr Comprehens Canc, Munster, Germany
基金
英国医学研究理事会;
关键词
miRNA; miR-148a; miR-106a; Chemotherapy; Resistance; PREGNANE-X-RECEPTOR; MICRORNA EXPRESSION PROFILES; NEOADJUVANT CHEMORADIOTHERAPY; BARRETTS-ESOPHAGUS; TUMOR-SUPPRESSOR; PROSTATE-CANCER; OVARIAN-CANCER; SURVIVAL; PROLIFERATION; CHOLANGIOCYTES;
D O I
10.1007/s11605-011-1418-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Response to chemotherapy varies widely in patients with advanced oesophageal cancer. We investigated the impact of manipulating certain microRNAs on response to cisplatin and 5-fluorouracil (5-FU) in oesophageal cancer cells. Methods Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed. Results The impact of miR-106a-upregulation was inconsistent. Upregulation was followed by reduced sensitivity to cisplatin in chemotherapy-sensitive EAC cells (cell survival, +8.7 +/- 0.8%; p = 0.003) and an improved response to 5-FU in cisplatin-resistant EAC cells (cell survival, -6.4 +/- 2.5%; p = 0.011). MiR-148a upregulation significantly increased sensitivity to chemotherapy in seven out of ten cell lines, represented by a decrease in cell viability of 22.6 +/- 7.9% to 50.5 +/- 10.6% after cisplatin (p <= 0.014) and 6.0 +/- 0.8% to 15.0 +/- 4.1% after 5-FU treatment (p <= 0.012). The only cell lines in which miR-148a upregulation had no effect were cisplatin-resistant EAC exposed to cisplatin and 5-FU-sensitive and 5-FU-resistant SCC cells exposed to 5-FU. Conclusion MiR-148a sensitized chemotherapy-sensitive oesophageal cancer cell lines to cisplatin and, to a lesser extent, to 5-flurouracil and attenuated resistance in chemotherapy-resistant variants. Further experimental and clinical studies to investigate the exact mechanisms involved are warranted.
引用
收藏
页码:429 / 438
页数:10
相关论文
共 50 条
  • [41] Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma
    S Hirajima
    S Komatsu
    D Ichikawa
    H Takeshita
    H Konishi
    A Shiozaki
    R Morimura
    M Tsujiura
    H Nagata
    T Kawaguchi
    T Arita
    T Kubota
    H Fujiwara
    K Okamoto
    E Otsuji
    [J]. British Journal of Cancer, 2013, 108 : 1822 - 1829
  • [42] A Novel Ras--Related Signature Improves Prognostic Capacity in Oesophageal Squamous Cell Carcinoma
    Yang, Hao-Shuai
    Liu, Wei
    Zheng, Shao-Yi
    Cai, He-Yuan
    Luo, Hong-He
    Feng, Yan-Fen
    Lei, Yi-Yan
    [J]. FRONTIERS IN GENETICS, 2022, 13
  • [43] MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells
    Shi, Lei
    Xi, Juanli
    Xu, Ximing
    Peng, Bo
    Zhang, Binghong
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 902 - 909
  • [44] Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma
    Wang, Honglei
    Jiang, Zeying
    Wang, Qihua
    Wu, Tong
    Guo, Fangzhou
    Xu, Zhengyuan
    Yang, Weixiong
    Yang, Shicong
    Feng, Shiting
    Wang, Xiaoyan
    Chen, Shuling
    Cheng, Chao
    Chen, Wenfang
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 186 : 196 - 210
  • [45] Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma?
    Smyth, Elizabeth C.
    [J]. LANCET ONCOLOGY, 2022, 23 (11): : 1363 - 1364
  • [46] Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma
    Miyagaki, H.
    Yamasaki, M.
    Miyata, H.
    Takahashi, T.
    Kurokawa, Y.
    Nakajima, K.
    Takiguchi, S.
    Fujiwara, Y.
    Ishii, H.
    Tanaka, F.
    Mori, M.
    Doki, Y.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 947 - 954
  • [47] Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma
    H Miyagaki
    M Yamasaki
    H Miyata
    T Takahashi
    Y Kurokawa
    K Nakajima
    S Takiguchi
    Y Fujiwara
    H Ishii
    F Tanaka
    M Mori
    Y Doki
    [J]. British Journal of Cancer, 2012, 106 : 947 - 954
  • [48] Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
    Chhabra, Arpit
    Ong, Leonard T.
    Kuk, Deborah
    Ku, Geoffrey
    Ilson, David
    Janjigian, Yelena Y.
    Wu, Abraham
    Schoeder, Heiko
    Goodman, Karyn A.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 (12) : 1658 - 1665
  • [49] RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma
    J Kurashige
    M Watanabe
    M Iwatsuki
    K Kinoshita
    S Saito
    Y Nagai
    T Ishimoto
    Y Baba
    K Mimori
    H Baba
    [J]. British Journal of Cancer, 2012, 107 : 1233 - 1238
  • [50] Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study
    Kauppila, Joonas H.
    Mattsson, Fredrik
    Brusselaers, Nele
    Lagergren, Jesper
    [J]. BMJ OPEN, 2018, 8 (05):